Jaguar Health (JAGX) Return on Capital Employed (2015 - 2026)
Jaguar Health's (JAGX) quarterly Return on Capital Employed came in at 131.73% in Q1 2026, up 26393.0% year-on-year from N/an in Q1 2025, and down 60.06% on a QoQ basis from 329.85% in Q4 2025.
Jaguar Health (JAGX) Return on Capital Employed (2015 - 2026) Analysis & Trends
Jaguar Health (JAGX) has 12 years of Return on Capital Employed data on file, last reported at 131.73% in Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 26393.0% year-over-year to 131.73% in Q1 2026; TTM through Mar 2026 was 131.73%, a 26393.0% increase from a year earlier, with the FY2025 full-year figure at 384.44%, up 47963.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 131.73%, down from 329.85% in the prior quarter.
- Over the last five years, Return on Capital Employed for JAGX reached as high as 329.85% in Q4 2025 and fell as low as 257.48% in Q3 2025.
- Historically, Return on Capital Employed has averaged 88.82% across 5 years, with a median of 128.51% in 2022.
- On a YoY basis, Return on Capital Employed climbed as much as 41492 bps in 2025 and fell as far as 18207 bps in 2025.
- Year by year, Return on Capital Employed stood at 180.84% in 2022, then surged by 44 bps to 100.61% in 2023, then increased by 15 bps to 85.07% in 2024, then surged by 488 bps to 329.85% in 2025, then slumped by 60 bps to 131.73% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 131.73% in Q1 2026, 329.85% in Q4 2025, and 257.48% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,782.24 Bn | 1,782.18 Bn | - | - |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | -107.40% |
| 3 | BeOne Medicines | 473.46 Bn | 468.66 Bn | 1.35 Bn | 10.46% |
| 4 | Vertex Pharmaceuticals | 123.84 Bn | 116.59 Bn | 2.59 Bn | 21.10% |
| 5 | Regeneron Pharmaceuticals | 71.69 Bn | 62.94 Bn | 3.31 Bn | 10.19% |
| 6 | Belite Bio | 62.15 Bn | 62.15 Bn | - | - |
| 7 | Argenx Se | 54.74 Bn | 49.55 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 38.08 Bn | 35.07 Bn | 959.66 Mn | 20.34% |
| 9 | Revolution Medicines | 36.07 Bn | 36.07 Bn | - | -68.84% |
| 10 | Jaguar Health | 520,945.88 | -9.54 Mn | 19.11 Mn | 131.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 131.73% |
| Dec 31, 2025 | 329.85% |
| Sep 30, 2025 | -257.48% |
| Jun 30, 2025 | -159.10% |
| Mar 31, 2025 | -132.20% |
| Dec 31, 2024 | -85.07% |
| Sep 30, 2024 | -75.41% |
| Jun 30, 2024 | -80.82% |
| Mar 31, 2024 | -92.62% |
| Dec 31, 2023 | -100.61% |
| Sep 30, 2023 | -90.91% |
| Jun 30, 2023 | -133.60% |
| Mar 31, 2023 | -154.10% |
| Dec 31, 2022 | -180.84% |
| Sep 30, 2022 | -164.75% |
| Jun 30, 2022 | -135.41% |
| Mar 31, 2022 | -128.51% |
| Dec 31, 2021 | -99.77% |
| Sep 30, 2021 | -66.82% |
| Jun 30, 2021 | -54.69% |